



Global Medical Grants

Oncology Investigator Sponsored Research Quarterly Application and Review Cycles

Investigator Sponsored Research (ISR)

Announcement for Oncology Assets Only

New! Starting January 1, 2021 – Quarterly Application and Review Cycles:

In order to provide a more efficient and transparent review process for the Oncology ISR program, we are pleased to announce the following application windows for 2021. Our commitment is to review all proposals and send out decision notifications by the notification deadlines below:

Submission Window

January 1 - March 31, 2021

April 1 - June 30, 2021

July 1 - October 8, 2021

October 9, 2021 - January 6, 2022

Notification deadline: *

May 19, 2021

August 18, 2021

December 1, 2021

February 24, 2022

* Please note that all studies involving avelumab will require 2-3 additional weeks beyond this date due to inter-company Alliance review schedules

Important note for applicants: Please do not wait until the submission deadline to enter your request into the online portal. Plan to apply early to allow time for clarification questions and to ensure completeness.

Proposals submitted to Pfizer in 2020 will be managed under the previous rolling review process.

Qualified researchers are invited to submit investigator-sponsored research (ISR) proposals, according to the guidance and instructions found on the Pfizer ISR portal at www.Pfizer.com/ISR. All proposals must be submitted via the ISR submission portal. An ISR proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for ISR submissions are made by the applicable Pfizer Global Review Committee. A formal notification regarding the status of your application will be sent on or before the posted notification date. Pfizer support will only be extended upon the execution of an ISR agreement. For any questions, please send an email to GlobalMedicalGrants@pfizer.com.

A list of Oncology assets available for ISR proposals, including Areas of Interest, are available on www.Pfizer.com/ISR. We are also announcing, as of January 2021, the addition of sasanlimab (anti-PD-1) to the list of available oncology products for independent investigation.